Search

Your search keyword '"Mitchell Brin"' showing total 6 results
Start Over Author "Mitchell Brin"
6 results on '"Mitchell Brin"'

1. New Classification and Management of Abetalipoproteinemia and Related Disorders

Author

Cindy Bredefeld, Noel Peretti, M. Mahmood Hussain, Mathilde Di Filippo, Ettie Granot, Charlotte Cuerq, Pierre Poinsot, Philippe Moulin, Sybil Charrière, Mitchell Brin, Richard J. Deckelbaum, Dennis D. Black, CarMeN, laboratoire, Long Island University, Brooklyn (LIU Brooklyn), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Medical Advisory Panel: Mathilde Di Filippo, Ettie Granot, Charlotte Cuerq, Pierre Poinsot, Philippe Moulin, Sybil Charrière, Mitchell Brin, Richard J Deckelbaum, Dennis D Black

Subjects
Pediatrics, medicine.medical_specialty, Lipoproteins, [SDV]Life Sciences [q-bio], Hyperlipidemia, Familial Combined, 030204 cardiovascular system & hematology, lipids, Hypobetalipoproteinemias, 03 medical and health sciences, 0302 clinical medicine, Malabsorption Syndromes, Pregnancy, medicine, Humans, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, Hepatology, business.industry, Gastroenterology, Abetalipoproteinemia, hypobetalipoproteinemia, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Pregnancy Complications, Hypobetalipoproteinemia, Familial, Apolipoprotein B, Apolipoprotein B-100, Female, Hypobetalipoproteinemia, business
Abstract

International audience; No abstract available

Published
2020
Full Text
View/download PDF

2. Spotlight on Abetalipoproteinemia and Related Hypobetalipoproteinemia Disorders: A Simplified Nomenclature and Clinical Guidelines. †

Author

Cindy Lee Bredefeld, Mahmood Hussain, Mathilde Di Filippo, Noel Peretti, Emile Levy, Mitchell Brin, Dennis Black, Richard Deckelbaum, Esther Granot, Charlotte Cuerq, Pierre Poinsot, and Philippe Moulin

Subjects
Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Internal Medicine, Cardiology and Cardiovascular Medicine
Published
2022
Full Text
View/download PDF

3. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Author

Kapil Dev Sethi, Stewart A. Factor, Charles H. Adler, and Mitchell Brin

Subjects
Dystonia, medicine.medical_specialty, business.industry, Neurological disorder, medicine.disease, Oromandibular dystonia, Dermatology, Botulinum toxin, eye diseases, nervous system diseases, Surgery, Neurology, otorhinolaryngologic diseases, Medicine, Botulism, In patient, Neurology (clinical), business, Intramuscular injection, Botulinum toxin type, medicine.drug
Abstract

Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.

Published
2001
Full Text
View/download PDF

4. Ocular Surface Erosion after Suspected Exposure to Evaporated COVID-19 Vaccine

Author

Somporn Chantra, Pareena Chaitanuwong, Kasem Seresirikachorm, Mitchell Brinks, Onsiri Serirat, Winston Chamberlain, and Paisan Ruamviboonsuk

Subjects
covid-19 vaccine, ocular surface erosion, skin rash, health worker, case report, Ophthalmology, RE1-994
Abstract

The purpose is to report ocular surface erosion of health personnel who were exposed to evaporated CoronaVac during a vaccination campaign. A campaign for CoronaVac vaccination was conducted in a closed space of 11.04 × 5.96 m, partially divided into 6 rooms with interconnected area among the rooms. A total of 20 health personnel worked in the vaccination rooms. On the third day of campaign, a vial, containing a single dose of 0.5 mL, of the vaccine was dropped accidentally onto the floor and broken by an administering nurse. A total of 15 personnel had symptoms and signs of ocular surface erosion at the average time from the accident to the onset of 10.2 ± 7.1 h; 4 personnel also had skin rash. These personnel included all 13 persons who already worked in the rooms when the accident occurred and continued for additional 4–6 h and 2 personnel who presented in the rooms 1–2 h after the accident and stayed for 2–3 h. Proximity and timing suggest CoronaVac correlation with the ocular and skin reactions. Cautions should be taken to avoid broken vials, spills, and aerosolization of CoronaVac during the vaccination.

Published
2021
Full Text
View/download PDF

5. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Author

Charles H, Adler, Stewart A, Factor, Mitchell, Brin, and Kapil D, Sethi

Subjects
Adult, Male, Dystonia, Neuromuscular Agents, Drug Resistance, Humans, Female, Mandibular Diseases, Botulinum Toxins, Type A, Middle Aged, Injections, Intramuscular, Aged
Abstract

Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results